Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine

Journal of Clinical Psychopharmacology

Volumn 23, Issue 2, 2003, Pages 119-127

  Carrillo, Juan Antonio ^a   Herráiz, Angustias G ^b   Ramos, Sara Isabel ^a   Gervasini, Guillermo ^a   Vizcaíno, Sonia ^a   Benítez, Julio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Psychiat Hosp Adolfo Diaz Ambrona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CIPROFLOXACIN; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEBRISOQUINE; FLUVOXAMINE; HALOPERIDOL; NORCLOZAPINE; OLANZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DELUSIONAL DISORDER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; HUMAN; MALE; MENTAL PATIENT; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SMOKING; STEADY STATE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SEX FACTORS; SMOKING; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 0037379568     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200304000-00003     Document Type: Article

References (58)

1. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30.
2. Bhana N, Foster RH, Olney R, et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001;61:111-61.
3. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38:393-414.
4. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-66.
5. Kassahun K, Mattiuz E, Nyhart E, Jr., et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25:81-93.
6. Hägg S, Spigset O, Lakso HA, et al. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 2001;57:493-7.
7. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37: 177-93.
8. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001;21:14-20.
9. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
10. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994;55:293-304.
11. Carrillo JA, Christensen M, Ramos SI, et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 2000;22:409-17.
12. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36:425-38.
13. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 1992;8:93-102.
14. Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999;156:1751-7.
15. Beratis S, Katrivanou A, Gourzis P. Factors affecting smoking in schizophrenia. Compr Psychiatry 2001;42:393-402.
16. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643-58.
17. Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996;41:605-8.
18. Tantcheva-Poór I, Zaigler M, Rietbrock S, et al. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999;9:131-44.
19. Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 1994;3: 675-82.
20. Schrenk D, Brockmeier D, Morike K, et al. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol 1998;53: 361-7.
21. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
22. Lingjærde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;76(334):1-100.
23. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
24. Lennard MS, Silas JH, Smith AJ, et al. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977;133:161-6.
25. Evans DAP, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
26. Benitez J, Llerena A, Cobaleda J. Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther 1988;44:74-7.
27. Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000;20:220-5.
28. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001;15:469-94.
29. McCreadie RG, Kelly C. Patients with schizophrenia who smoke: private disaster, public resource. Br J Psychiatry 2000;176:109.
30. Gulbinat W, Dupont A, Jablensky A, et al. Cancer incidence of schizophrenic patients: results of record linkage studies in three countries. Br J Psychiatry Suppl 1992:75-83.
31. Carrillo JA, Benitez J. Are antipsychotic drugs potentially chemopreventive agents for cancer? Eur J Clin Pharmacol 1999;55:487-8.
32. Lichtermann D, Ekelund J, Pukkala E, et al. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry 2001;58:573-8.
33. Mortensen PB. The incidence of cancer in schizophrenic patients. J Epidemiol Community Health 1989;43:43-7.
34. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993;163:183-9.
35. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
36. Özdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 2001;21:398-407.
37. Özdemir V, Kalow W, Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C→A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 2001;21:603-7.
38. Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 2001;21:569-74.
39. Dong SX, Ping ZZ, Xiao WZ, et al. Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. Ther Drug Monit 1998;20:371-5.
40. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999;369:11-23.
41. Sachse C, Brockmöller J, Bauer S, et al. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9.
42. Callaghan JT, Cerimele BJ, Kassahun KJ, et al. Olanzapine: interaction study with imipramine. J Clin Pharmacol 1997;37:971-8.
43. McCarthy RH. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 1994;27:210-1.
44. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000;39:127-53.
45. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 1999;40: 101-4.
46. Ring BJ, Binkley SN, Vandenbranden M, et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996;41:181-6.
47. Wrighton SA, Ring BJ. Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience. Drug Metab Rev 1999;31:15-28.
48. Gomberg RF. Interaction between olanzapine and haloperidol [letter]. J Clin Psychopharmacol 1999;19:272-3.
49. Shimoda K, Someya T, Morita S, et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther Drug Monit 1999;21:293-6.
50. Macias WL, Bergstrom RF, Cerimele BJ, et al. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy 1998;18:1237-48.
51. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993;45:1211-4.
52. Mäenpää J, Wrighton S, Bergstrom R, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine [abstract]. Clin Pharmacol Ther 1997;61:225.
53. de Jong J, Hoogenboom B, van Troostwijk LD, et al. Interaction of olanzapine with fluvoxamine. Psychopharmacology (Berlin) 2001; 155:219-20.
54. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001;23:410-3.
55. Markowitz JS, DeVane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration [letter]. J Clin Psychopharmacol 1999;19:289-91.
56. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999;21:87-90.
57. Licht RW, Olesen OV, Friis P, et al. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine [letter]. J Clin Psychopharmacol 2000;20:110-2.
58. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 1998;54:639-43.